Skip to main content
. 2012 Aug 9;3:226. doi: 10.3389/fmicb.2012.00226

Figure 1.

Figure 1

Structure of inhibitors used in this study. (1) Fosmidomycin (Fos, 3-[formyl(hydroxy) amino] propylphosphonic acid). (2) FR900098 (3-[acetyl(hydroxy)amino] propylphosphonic acid). (3) Compound 1: acyloxyalkyl ester prodrug derivative of FR900098 (Ortmann et al., 2003).